Analysis of 1028 statins-related medication errors and prevention strategies

doi:10.19803/j.1672-8629.2022.06.13

Abstract

Abstract: Objective To investigate the incidence and causes of medication errors (ME) related to statins in China in order to formulate targeted preventive measures and ensure the safety of drug use in patients. Methods ME reports were collected from the National Monitoring Network for Clinical Safe Drug Use from January 1, 2016 to December 31, 2020, and analyzed in terms of the origin, classification, drugs involved, types of errors, personnel responsible, discovers of errors and causes of errors. Results A total of 1 028 ME reports were collected from 132 hospitals in 23 provinces and cities. Most of these reports involved grade B errors (848 cases, 82.49%), and there were 5 cases of severe ME (0.49%). Many of these errors were related to the variety, involving 300 cases (29.10%, LASA drugs). The five serious ME errors involved drugs interactions (2 cases), contraindications (1 case), dosage (1 case), and repeated administration (1 case). Those most responsible for ME were doctors, involving 515 cases (50.10%, and the main cause of errors was repeated administration). 849 cases of errors (79.72%) were found by pharmacists. Most of these ME were due to human factors, involving 590 cases (52.73%, mainly because of fatigue and lack of knowledge). Conclusion Statins-related ME are mostly of grade B and caused by LASA. It is recommended that clinicians be better informed of rational drug use, and that the stress of health care providers be reduced so as to lower the risk of LASA errors and ensure the drug safety of patients.

Key words: statins, medication errors, medication safety, risk prevention

CLC Number:

R994.1

SHAO Chen, ZHANG Qingxia, YAN Suying, WANG Yuqin. Analysis of 1028 statins-related medication errors and prevention strategies[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 645-648.

References

[1] Joint Committee on the revision of guidelines for the prevention and treatment of dyslipidemia in adults in China. Guidelines for the prevention and treatment of dyslipidemia in adults in China (2016 Revised Edition)[J]. Chinese Circulation Journal(中国循环杂志),2016, 31(10): 937-950.
[2] ZHANG QX, ZHANG YZ, ZENG Y, et al.Analysis of medication errors in patients with hyperuricemia/gout based on national monitoring network for clinical safe drug use[J]. China Pharmacy(中国药房), 2021, 32(15): 1894-1898.
[3] ZHANG QX, WANG YW, LI XL, et al.Annual report of national monitoring network for clinical safe medication(2020)[J]. Adverse Drug Reactions Journal(药物不良反应杂志),2021, 23(5): 228-234.
[4] JIA AS, LI XL.Summary of the conference on the establishment and the First Working Meeting of the Medication Safety Panel in China Core Group of International Network for the Rational Use of Drugs[J]. Adverse Drug Reactions Journal(药物不良反应杂志),2012, 14(5): 335-337.
[5] ZHANG QX, WANG YW, LI XL, et al.Annual report on clinical medication safety of National Monitoring Network for Clinical Safe Medication(2018)[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2019, 21(1): 2-8.
[6] ZHANG QX, WANG YW, LI XL, et al.Annual report on clinical medication safety of National Monitoring Network for Clinical Safe Medication(2019)[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2020, 22(9): 499-504.
[7] Medication Safety Panel in China Core Group of International Network for the Rational Use of Drug(INRUD), Chinese Pharmacological Society Professional Committee of Drug-induced Diseases, Chinese Pharmaceutical Association Professional Committee of Hospital Pharmacy, et al. Expert consensus on medication error management in China[J]. Journal of Adverse Drug Reactions(药物不良反应杂志), 2014, 16(6): 321-326.
[8] ZHANG QX, YAN SY, LI XL, et al.Analysis on reports of medication errors with methotrexate tablets in National Monitoring Network for Clinical safe Medication from 2012 to 2017[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2018, 20(3): 187-192.
[9] WANG ZM, ZHANG QX, YAN SY, et al.Analysis of reports on medication error in our hospital from 2016 to 2017[J]. Practical Pharmacy And Clinical Remedies(实用药物与临床),2019, 22(12): 1324-1327.
[10] BATES DW, CULLEN DJ, LAIRD N, et al.Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group[J]. JAMA, 1995, 274(1): 29-34.
[11] WANG J, CUI XH, JIANG DC, et al.The establishment of prescription pre-examination system and its effect on the quality of the prescription in the outpatients and emergency patients[J]. Clinical Medication Journal(临床药物治疗杂志), 2018, 16(9):68-71.
[12] CUI XH, YAN SY, JIANG DC, et al.Design and preliminary application of pre-audit system for medical orders in hospitalized patients[J]. Adverse Drug Reactions Journal(药物不良反应杂志),2018, 20(2): 122-127.
[13] SHAO C, CHU YQ, CUI XH, et al.The effect of prescription pre-checking system in inpatient medication safety[J]. Clinical Medication Journal(临床药物治疗杂志), 2020, 18(1): 51-54.
[14] ZHANG H, JIA N, ZHANG YT, et al.Analysis of Effects of Drug-drug Interactions on Safety and Efficacy of Atorvastatin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(1): 43-46.
[15] ZHANG X, GU YX.Literature review of 141 cases of adverse drug reactions induced by simvastatin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(8): 487-491.